Method and device for extracting gene fusion immune treatment neoantigen by integrating deep sequencing data of DNA and RNA

Abstract

The invention discloses a method and a device for extracting a gene fusion immune treatment neoantigen by integrating deep sequencing data of DNA and RNA. The method comprises the following steps: S10, acquiring a genome gene fusion sequence of a sample; S20, acquiring a transcriptome gene fusion sequence of the sample; S30, constructing a gene fusion proteome; and S40, obtaining a sample neoantigen. The tumor specific neoantigens discovered by the scheme of the invention are all from gene fusion, so that the screening range of the neoantigens is expanded, and an ammunition library of an immune treatment method based on the neoantigens is enriched. Through analysis and integration of tumor sample whole exome sequencing data and transcriptome sequencing data, gene fusion events in tumor tissues are comprehensively detected, the false positive rate of neoantigens generated by fusion is reduced, the effectiveness of neoantigen vaccine is improved, and the method is of great significance to improvement of the clinical immune treatment effect.

Description

technical field [0001] The invention relates to the field of tumor immunotherapy, in particular to a method and a device for extracting neoantigens for gene fusion immunotherapy by integrating deep sequencing data of DNA and RNA. Background technique [0002] Therapeutic concepts and methods for malignant tumors have been deeply developed in the past few decades. Traditional tumor treatment methods include surgery, radiotherapy, radiotherapy, and targeted therapy based on mutation typing. However, the above treatments have certain limitations in terms of toxic side effects and drug resistance. In recent years, new breakthroughs have been made in the concept of immunotherapy that inhibits and kills tumor cells by activating the immune system. Existing immunotherapy methods can be divided into three categories according to their mechanism of action: (1). Immune checkpoint inhibitors that activate the immune system by inhibiting the inhibitory pathway of the immune system, (2)...

AI Technical Summary

Problems solved by technology

However, since the identification of gene fusions based on a single data source (DNA or RNA) usually has high false positives, prediction of neoantigens generated by fusion requires more abundant data and a strict screening process to ensure the high efficiency of neoantigen vaccines

Images